On this page

VITAMIN D

ergocalciferol · Capsule

Prescription ANDA TE AA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
VITAMIN D
Generic name
ergocalciferol
Dosage form
Capsule
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Preferred Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
10
Packages
43
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ergocalciferol 1.25 mg/1 1367410 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Capsule
Route of administration
Oral
Presentations
53

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Ergocalciferols [CS] CS All 12 members
Provitamin D2 Compound [EPC] EPC 4 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
090455
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 3, 2010
Sponsor
ONESOURCE
Products on application
1
Submissions recorded
1
Products approved under application 090455.
Product Trade name Form Strength Ingredient Status TE Flags
090455-001 ERGOCALCIFEROL CAPSULE ERGOCALCIFEROL Prescription AA RS

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 090455.
Type No. Action Status Date Review
Original application 1 Approved August 3, 2010 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251007). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251007 HUMAN PRESCRIPTION DRUG · 20250415 HUMAN PRESCRIPTION DRUG · 20220401

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 USP Units daily. Hypoparathyroidism: 50,000 to 200,000 USP Units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss. Call your doctor for medical advice about side effects. You may report side effects to Strides Pharma Inc. at 1-877-244-9825 or go to www.strides.com

Drug Interactions

openFDA Drug Labeling

Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Ergocalciferol Capsules, USP may cause hypercalcemia.

Description

openFDA Drug Labeling

DESCRIPTION Ergocalciferol Capsules, USP are a synthetic calcium regulator for oral administration. Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D 2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP unit of vitamin D 2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D 2 is equal to 40 USP Units. Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units in an edible vegetable oil. Ergocalciferol, also called vitamin D 2 , is 9,10-secoergosta-5,7,10(19), 22-tetraen-3-ol, (3β,5Z,7E,22 E )-; (C 28 H 44 O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients: 2-Ethoxyethanol, FD&C Blue #1, FD&C Yellow #5, Gelatin, Glycerin, Lecithin, Medium chain triglyceride, Purified water, Shellac glaze (modified) IN SD-45, Simethicone, Soybean oil and Titanium dioxide. Vitamin D structure

OVERDOSAGE The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by: 1. Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis. 2. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. 3. Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly. 4. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism). The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported. The LD 50 in animals is unknown. The toxic oral dose of ergocalciferol in the dog is 4 mg/kg.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units. The green colored oval shaped transparent soft gelatin capsules are imprinted with '194' in white and contain clear light yellow oily liquid. Bottles of 06 capsules (NDC: 63187-519-06) Bottles of 08 capsules (NDC: 63187-519-08) Bottles of 12 capsules (NDC: 63187-519-12) Bottles of 16 capsules (NDC: 63187-519-16) Bottles of 30 capsules (NDC: 63187-519-30) Bottles of 60 capsules (NDC: 63187-519-60) Bottles of 90 capsules (NDC: 63187-519-90) Store at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light. Manufactured By: Strides Pharma Science Ltd. Bengaluru - 562106, India. Distributed By: Strides Pharma Inc 201 South Main Street, Suite 3 Lambertville, NJ 08530 USA (06-2014) Repackaged By: Proficient Rx LP Thousand Oaks, CA 91320

Adverse event reports

Source: openFDA FAERS
382,603
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ERGOCALCIFEROL. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
71610-552-03 71610-552 Aphena Pharma Solutions - Tennessee, LLC 3 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-03) June 20, 2024
71610-552-04 71610-552 Aphena Pharma Solutions - Tennessee, LLC 4 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-04) May 4, 2021
71610-552-06 71610-552 Aphena Pharma Solutions - Tennessee, LLC 6 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-06) June 16, 2026
71610-552-08 71610-552 Aphena Pharma Solutions - Tennessee, LLC 8 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-08) November 12, 2024
71610-552-09 71610-552 Aphena Pharma Solutions - Tennessee, LLC 9 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-09) June 16, 2026
71610-552-12 71610-552 Aphena Pharma Solutions - Tennessee, LLC 12 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-12) May 4, 2021
71610-552-13 71610-552 Aphena Pharma Solutions - Tennessee, LLC 13 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-13) August 25, 2023
71610-552-25 71610-552 Aphena Pharma Solutions - Tennessee, LLC 25 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-25) June 16, 2026
71610-552-47 71610-552 Aphena Pharma Solutions - Tennessee, LLC 24 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-47) November 19, 2025
71610-552-49 71610-552 Aphena Pharma Solutions - Tennessee, LLC 5 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-49) June 16, 2026
71610-552-68 71610-552 Aphena Pharma Solutions - Tennessee, LLC 26 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-68) November 19, 2025
50268-297-15 50268-297 AvPAK 50 BLISTER PACK in 1 BOX (50268-297-15) / 1 CAPSULE in 1 BLISTER PACK (50268-297-11) April 7, 2020
71335-0278-0 71335-0278 Bryant Ranch Prepack 45 CAPSULE in 1 BOTTLE (71335-0278-0) March 18, 2015
71335-0278-1 71335-0278 Bryant Ranch Prepack 12 CAPSULE in 1 BOTTLE (71335-0278-1) March 18, 2015
71335-0278-2 71335-0278 Bryant Ranch Prepack 30 CAPSULE in 1 BOTTLE (71335-0278-2) March 18, 2015
71335-0278-3 71335-0278 Bryant Ranch Prepack 100 CAPSULE in 1 BOTTLE (71335-0278-3) March 18, 2015
71335-0278-4 71335-0278 Bryant Ranch Prepack 4 CAPSULE in 1 BOTTLE (71335-0278-4) March 18, 2015
71335-0278-5 71335-0278 Bryant Ranch Prepack 20 CAPSULE in 1 BOTTLE (71335-0278-5) March 18, 2015
71335-0278-6 71335-0278 Bryant Ranch Prepack 8 CAPSULE in 1 BOTTLE (71335-0278-6) March 18, 2015
71335-0278-7 71335-0278 Bryant Ranch Prepack 15 CAPSULE in 1 BOTTLE (71335-0278-7) March 18, 2015
71335-0278-8 71335-0278 Bryant Ranch Prepack 120 CAPSULE in 1 BOTTLE (71335-0278-8) March 18, 2015
71335-0278-9 71335-0278 Bryant Ranch Prepack 60 CAPSULE in 1 BOTTLE (71335-0278-9) March 18, 2015
51407-700-01 51407-700 Golden State Medical Supply, Inc. 100 CAPSULE in 1 BOTTLE, PLASTIC (51407-700-01) October 11, 2024
51655-774-27 51655-774 Northwind Health Company, LLC 12 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-27) September 21, 2022
51655-774-52 51655-774 Northwind Health Company, LLC 30 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-52) January 27, 2023
51655-774-80 51655-774 Northwind Health Company, LLC 8 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-80) August 29, 2022
72789-249-01 72789-249 PD-Rx Pharmaceuticals, Inc. 100 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-01) May 5, 2022
72789-249-12 72789-249 PD-Rx Pharmaceuticals, Inc. 12 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-12) May 5, 2022
72789-249-13 72789-249 PD-Rx Pharmaceuticals, Inc. 13 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-13) May 5, 2022
68788-7627-1 68788-7627 Preferred Pharmaceuticals, Inc. 100 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-1) June 1, 2020
68788-7627-2 68788-7627 Preferred Pharmaceuticals, Inc. 12 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-2) June 1, 2020
68788-7627-3 68788-7627 Preferred Pharmaceuticals, Inc. 30 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-3) June 1, 2020
68788-7627-8 68788-7627 Preferred Pharmaceuticals, Inc. 8 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-8) June 1, 2020
63187-519-06 63187-519 Proficient Rx LP 6 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-06) October 2, 2017
63187-519-08 63187-519 Proficient Rx LP 8 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-08) January 1, 2016
63187-519-12 63187-519 Proficient Rx LP 12 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-12) October 28, 2020
63187-519-16 63187-519 Proficient Rx LP 16 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-16) February 1, 2016
63187-519-30 63187-519 Proficient Rx LP 30 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-30) August 3, 2015
63187-519-60 63187-519 Proficient Rx LP 60 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-60) August 3, 2015
63187-519-90 63187-519 Proficient Rx LP 90 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-90) August 3, 2015
70518-1878-1 70518-1878 REMEDYREPACK INC. 12 CAPSULE in 1 BOTTLE, PLASTIC (70518-1878-1) August 28, 2019
64380-737-06 64380-737 Strides Pharma Science Limited 100 CAPSULE in 1 BOTTLE, PLASTIC (64380-737-06) May 16, 2014
64380-737-25 64380-737 Strides Pharma Science Limited 50 CAPSULE in 1 BOTTLE, PLASTIC (64380-737-25) May 16, 2014
71610-552 71610-552 Aphena Pharma Solutions - Tennessee, LLC — May 16, 2014
50268-297 50268-297 AvPAK — April 7, 2020
71335-0278 71335-0278 Bryant Ranch Prepack — May 16, 2014
51407-700 51407-700 Golden State Medical Supply, Inc. — August 3, 2010
51655-774 51655-774 Northwind Health Company, LLC — August 29, 2022
72789-249 72789-249 PD-Rx Pharmaceuticals, Inc. — May 16, 2014
68788-7627 68788-7627 Preferred Pharmaceuticals, Inc. — June 1, 2020
63187-519 63187-519 Proficient Rx LP — May 16, 2014
70518-1878 70518-1878 REMEDYREPACK INC. — February 18, 2019
64380-737 64380-737 Strides Pharma Science Limited — May 16, 2014

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.